References
- Canellos G P, Anderson J R, Propert K J, Nissen N, Cooper M R, Henderson E S, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. New Engl J Med 1992; 327: 1478–1484
- Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New Engl J Med 2003; 348: 2386–2395
- Horning S J, Hoppe R T, Breslin S, Bartlett N L, Brown B W, Rosenberg S A. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630–637
- Hancock S L, Hoppe R T. Long term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiot Oncol 1996; 6: 225–242
- Eich H T, Gossmann A, Engert A, Kriz J, Bredenfeld H, Hansemann K, et al. A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2007; 69: 1187–1192
- Diehl V, Kobe C, Haverkamp H, Dietlein M, Engert A. FDG-PET for assessment of residual tissue after completion of chemotherapy in Hodgkin's lymphoma – report on the 2nd interim analysis of the PET investigation in the trial HD15 of the GHSG. Blood (Suppl.) 2007; 110: 70a
- Meyer R M, Gospodarowicz M K, Connors J M, Pearcy R G, Bezjak A, Wells W A, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634–4642
- Straus D J, Portlock C S, Qin J, Myers J, Zelenetz A D, Moskowitz C, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 3483–3489
- Belgaumi A, Al-Kofide A, Joseph N, Jamil-Malik R, Khafaga Y, Sabbah R. Hodgkin lymphoma in very young children: clinical characteristics and outcome of treatment. Leuk Lymphoma
- Chow L ML, Nathan P C, Hodgson D C, Jenkin D, Weitzman S, Grant R M, et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low dose, extended field irradiation. J Clin Oncol 2006; 24: 5735–5741
- Schwartz C L. The management of Hodgkin disease in the young child. Curr Opin Pediatr 2003; 15: 10–16
- Stoneham S, Ashley S, Pinkerton R, Hewitt M, Wallace W H, Shankar A G, et al. Hodgkin's lymphoma in children aged 5 years or less – the United Kingdom experience. Eur J cancer 2007; 23: 1415–1421
- Boleti E, Mead G M. ABVD for Hodgkin's lymphoma: full dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007; 18: 376–380
- Evens A, Cilley J, Ortiz T, Gounder M, Hou N, Rademaker A, et al. G-CSF is not necessary to maintain over 99% dose intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10 year analysis. Br J Haematol 2007; 137: 545–552